Acumen Pharmaceuticals Inc.

58 articles about Acumen Pharmaceuticals Inc.

• Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

  11/13/2023

  Acumen Pharmaceuticals, Inc. announced that it has entered into a senior secured loan and security agreement with K2 HealthVentures, a healthcare-focused specialty finance company.

• Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

  11/13/2023

  Acumen Pharmaceuticals, Inc. reported financial results for the third quarter of 2023 and provided a business update.

• Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

  11/7/2023

  Acumen Pharmaceuticals, Inc. announced that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 14, 2023 at 2:25 p.m. ET.

• Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

  11/6/2023

  Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics Inc.

• Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

  11/6/2023

  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter financial results on Monday, Nov. 13, 2023.

• Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference - November 02, 2023

  11/2/2023

  Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced that management will participate in a fireside chat at the UBS Biopharma Conference on Thursday, Nov. 9, 2023 at 10:00 a.m. ET.

• Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease

  10/27/2023

  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today presented further analyses of the Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AβO-targeting antibody, at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston and online.

• Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

  10/4/2023

  Acumen Pharmaceuticals, Inc. today announced that it will present deeper insights and new exploratory findings from its Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AβO-directed antibody therapy for early AD, at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in Boston and online from October 24-27, 2023.

• Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

  9/19/2023

  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a panel discussion at the Cantor Global Healthcare Conference on Tuesday, Sept. 26, 2023 at 9:20 a.m. ET.

• Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

  9/6/2023

  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, Sept. 13, 2023 at 10:30 a.m. ET.

• Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

  8/8/2023

  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the second quarter of 2023 and provided a business update.

• Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023

  8/1/2023

  Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced that the Company will report second quarter financial results on Tuesday, August 8, 2023.

• Acumen Announces Pricing of Upsized $130 Million Public Offering

  7/19/2023

  Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS) today announced the pricing of an upsized underwritten public offering of 16,774,193 shares of its common stock at a price to the public of $7.75 per share.

• Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease

  7/17/2023

  Acumen Pharmaceuticals, Inc.  will hold a conference call today to discuss the positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD.

• Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock - July 17, 2023

  7/17/2023

  Acumen Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering of $100 million of shares of its common stock.

• Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

  7/16/2023

  Acumen Pharmaceuticals, Inc. presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD, at the Alzheimer’s Association International Conference 2023, taking place in Amsterdam and online from July 16-20, 2023.

• Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023

  6/13/2023

  Acumen Pharmaceuticals, Inc. announced that it will present topline results from a Phase 1 trial of its candidate ACU193, the first clinical stage AβO-directed antibody therapy, at the Alzheimer’s Association International Conference 2023 taking place in Amsterdam, Netherlands and online from July 16-20, 2023.

• Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights

  5/9/2023

  Acumen Pharmaceuticals, Inc. reported financial results for the first quarter of 2023 and provided a business update.

• Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference

  5/4/2023

  Acumen Pharmaceuticals, Inc. announced that management will participate in a fireside chat at the 2023 Bank of America Healthcare Conference on Thursday, May 11, 2023 at 8:00 a.m. PT.

• Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

  5/2/2023

  Acumen Pharmaceuticals, Inc. announced that the Company will report first quarter financial results on Tuesday, May 9, 2023.